ISLB 2020

Nov 12, 2020

The Epic Sciences team presented at the virtual ISLB 2020 Annual Congress Meeting – October 30, 2020.

CTC + ctDNA: Accelerating Clinical Drug Development

About this presentation:

Epic Sciences and Predicine have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLAS, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw.

Download the presentation slides or watch presentation with narration

Presented by:

Shidong Jia, MD, PhD

Founder & CEO


Richard Wenstrup, MD

Chief Medical Officer

Epic Sciences